Paper Details

  1. Home
  2. Paper Details

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.

Author: , BlackorbyAllison, CarrollKevin, CizmanBorut, CobitzAlexander R, DaviesRich, DoleJo, JhaVivekanand, JohansenKirsten L, KlerLata, LopesRenato D, MacdougallIain C, McMurrayJohn J V, MeadowcroftAmy M, ObradorGregorio T, PerkovicVlado, SinghAjay K, SolomonScott, WaikarSushrut S, WannerChristoph, WheelerDavid C, WięcekAndrzej, ZhuXinyi

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This abstract discusses the use of hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHIs) as an alternative to erythropoiesis-stimulating agents (ESAs) for treating anemia in patients with chronic kidney disease (CKD). PHIs have been shown to be as effective as ESAs in increasing hemoglobin levels.
Paper Details　
Original Abstract of the Article :
Among patients with chronic kidney disease (CKD), the use of recombinant human erythropoietin and its derivatives for the treatment of anemia has been linked to a possibly increased risk of stroke, myocardial infarction, and other adverse events. Several trials have suggested that hypoxia-inducible ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2113379

データ提供：米国国立医学図書館（NLM）

Daprodustat: A New Route Through the Anemia Desert

Anemia, a common complication in patients with chronic kidney disease (CKD), can feel like a long, arduous journey through a desert of fatigue and weakness. This study explores the potential of daprodustat, a new drug that stimulates red blood cell production, for managing anemia in patients undergoing dialysis.

The research team investigates the potential of daprodustat, a new drug that stimulates red blood cell production, to manage anemia in patients undergoing dialysis. The study highlights the potential risks associated with traditional anemia treatments, such as recombinant human erythropoietin, which can increase the risk of stroke and other adverse events. This finding provides a valuable perspective on the need for alternative treatment approaches for managing anemia in CKD patients.

Finding a Safer Path: Managing Anemia in Dialysis Patients

This study suggests that daprodustat may offer a safer alternative for managing anemia in dialysis patients. The findings emphasize the need to explore new treatment options for anemia, particularly in vulnerable patient populations, where traditional treatments may carry significant risks.

Navigating the Anemia Desert: A New Oasis of Hope

The potential of daprodustat to manage anemia in dialysis patients offers a glimmer of hope for improving the quality of life for these individuals. This study encourages further research into the safety and effectiveness of this promising new treatment approach.

Dr.Camel's Conclusion

This study explores the potential of daprodustat, a new drug, for managing anemia in dialysis patients. The findings highlight the need for safer and more effective treatments for anemia in this vulnerable population. This research encourages further investigation into daprodustat, potentially offering a new oasis of hope for patients struggling with anemia.

Date :
  1. Date Completed 2021-12-28
  2. Date Revised 2022-12-28
Further Info :

Pubmed ID

34739194

DOI: Digital Object Identifier

10.1056/NEJMoa2113379

Related Literature

Article Analysis
・Effects of darbepoetin alfa injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.